Hikma Pharmaceuticals Fair Value
HI
The fair market value of HIK.L stock is 1004.79 GBX. Relative to the market price of 1837 GBX Hikma Pharmaceuticals is overvalued by 45.3%
Eyestock's quantitative valuation approach is based on the method of estimating historical multipliers. To determine whether a stock is undervalued, we compare its current price to our estimated of fair value. The more undervalued a stock is, the more investment is profitable.
Fair Relative Value
Hikma Pharmaceuticals Valuation
Current HIK.L share ticker price is 1837 GBX.
The fair value level of 1004.79 GBX can be considered as an effective entry point for long-term investors to start investing in HIK.L stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
Current market price
Current price is 45% higher its fair value
Current price is 55% higher its minimum value
Current price is 6% higher its maximum value
Market price:
HIK.L stock is greatly overvalued
It means the current price may concern as a High Risk Entry Point
Hikma Pharmaceuticals PLC Stock Valuation Calculator
How do we value a stock?
As fair value, we use the product of the median Price-to-earnings ratios at the end of each reporting period for the last 5 years and earnings per share for the last 12 months. By analogy with the fair value, we calculate the maximum and minimum ones using the corresponding P/E extremums.
1
Maximum P/E over 5 years
15.55
2
Median P/E over 5 years
9.08
3
Minimum P/E over 5 years
7.45
4
Earning per share (last 12 months)
1.42 USD
Maximum value
1
x
4
=
1 719.74 GBX
Fair value
2
x
4
=
1 004.79 GBX
Minimum value
3
x
4
=
823.89 GBX
Hikma Pharmaceuticals PLC price metrics
-0.58
Annual return (geometric mean)
28.86
Risk (standard deviation) of returns
β
0.67
Beta (volatility compared to market)